refractory anemia with excess blasts

refractory anemia with excess blasts

Hematology A myelodysplastic syndrome of older persons characterized by anemia or pancytopenia and BM hypercellularity Clinical Nonspecific–anemia of gradual onset, fatigue, weakness, exacerbation of underlying heart disease Lab Anisocytosis, megaloblastoid maturation of erythroid precursors, thrombocytopenia; 5-20% of the BM cells are blasts; < 5% of peripheral cells are blasts Prognosis Guarded; average Pt survives < 1 yr; ±14 undergo leukemic transformation, usually into ANLL Treatment Not all Pts require therapy;13 die of bleeding or infectious complication linked to pancytopenia; intensive chemotherapy may substitute one cause of M&M for another; cytokines and growth factors may be effective. See Myelodysplastic syndrome, PISA.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
14 patients had refractory anemia (RA), six had an isolated deletion of the long arm of chromosome 5 (del(5q)), 5 had refractory anemia with ring sideroblasts (RARS), 17 had refractory cytopenia with multilineage dysplasia (RCMD), 15 had refractory anemia with excess blasts 1 (RAEB-1), and 19 had RAEB-2.
1RA, refractory anemia; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts. Table 3: The absolute number of cell populations in the peripheral blood of patients with MDS and age-matched healthy donors (109 cells/L).
Eveillard, "Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q)," Blood, vol.
[USPRwire, Tue Nov 03 2015] GlobalData's clinical trial report, "Refractory Anemia With Excess Blasts Global Clinical Trials Review, H2, 2015" provides an overview of Refractory Anemia With Excess Blasts clinical trials scenario.
According to World Health Organization criteria (23), the patients were classified as follows: 8 cases of refractory anemia, 7 cases of refractory anemia with ringed sideroblasts, 7 cases of refractory anemia with excess blasts, and 8 cases of refractory anemia with excess blasts in transformation.
Refractory anemia with excess blasts subtype 2 (RAEB-2) belongs to the most severe subgroups of myelodysplastic syndrome (MDS), a group of heterogeneous oncohematological bone marrow disorders characterized by ineffective hematopoiesis, blood cytopenias, and a progression of the disease toward acute myeloid leukemia (AML).
In three previous proteomic studies of different MDS subgroups, plasma proteome changes were interrogated in MDS patients with refractory anemia, refractory anemia with ringed sideroblasts (RA-RARS) [9], refractory cytopenia with multilineage dysplasia (RCMD) [10], and refractory anemia with excess blasts subtype 1 (RAEB-1) [11].
At this time, blasts constituted 6% of marrow cells and the morphologic findings met the criteria for the WHO category of refractory anemia with excess blasts. The marrow was also significant for extensive fibrosis (Figure 1(c)) and a few blasts with megakaryocytic features (Figure 1(d)).
Of the nine cases of myelodysplastic syndrome four were refractory anemia, two were refractory cytopenia with multilineage dysplasia, one was refractory Anemia with Ring sideroblast and two cases of refractory Anemia with excess blasts which compares with the similar study conducted in India 4.
Dacogen was approved by the U.S Food and Drug Administration (FDA) on May 2, 2006 for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.
M, male; F, female; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; ND, not described; IP, interstitial pneumonia.